drugset / Trial / NCT02168595

Placebo-controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of GMI-1271 in Healthy Volunteers

NCT02168595

Phase 1 Completed 28 enrolled GlycoMimetics Incorporated
RandomizedSingle-groupDouble-blindOther

Summary

The purpose of this study is to evaluate safety, tolerability and pharmacokinetics of single ascending IV doses of GMI-1271 in healthy adult subjects.

Timeline

Start
2014-06
Primary completion
2014-08
Completion
2015-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Uproleselan Small molecule 2 mg/kg Intravenous
Subject Uproleselan Small molecule 5 mg/kg Intravenous
Subject Uproleselan Small molecule 10 mg/kg Intravenous

Indications

No indication recorded.